Skip Navigation


Human Molecular Genetics Advance Access originally published online on August 8, 2005
Human Molecular Genetics 2005 14(18):2717-2726; doi:10.1093/hmg/ddi305
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
14/18/2717    most recent
ddi305v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (23)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Proks, P.
Right arrow Articles by Ashcroft, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Proks, P.
Right arrow Articles by Ashcroft, F. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Functional effects of KCNJ11 mutations causing neonatal diabetes: enhanced activation by MgATP

Peter Proks, Christophe Girard and Frances M. Ashcroft*

University Laboratory of Physiology, Oxford University, Parks Road, Oxford, OX1 3PT, UK

* To whom correspondence should be addressed. Tel: +44 1865285810; Fax: +44 1865285812; Email: frances.ashcroft{at}physiol.ox.ac.uk

Received June 10, 2005; Accepted August 3, 2005

Recent studies have shown that heterozygous mutations in KCNJ11, which encodes Kir6.2, the pore-forming subunit of the ATP-sensitive potassium (KATP) channel, cause permanent neonatal diabetes either alone (R201C, R201H) or in association with developmental delay, muscle weakness and epilepsy (V59G,V59M). Functional analysis in the absence of Mg2+, to isolate the inhibitory effects of ATP on Kir6.2, showed that both types of mutation reduce channel inhibition by ATP. However, in pancreatic ß-cells, KATP channel activity is governed by the balance between ATP inhibition via Kir6.2 and Mg-nucleotide stimulation mediated by an auxiliary subunit, the sulphonylurea receptor SUR1. We therefore studied the MgATP sensitivity of KCNJ11 mutant KATP channels expressed in Xenopus oocytes. In contrast to wild-type channels, Mg2+ dramatically reduced the ATP sensitivity of heterozygous R201C, R201H, V59M and V59G channels. This effect was predominantly mediated via the nucleotide-binding domains of SUR1 and resulted from an enhanced stimulatory action of MgATP. Our results therefore demonstrate that KCNJ11 mutations increase the current magnitude of heterozygous KATP channels in two ways: by increasing MgATP activation and by decreasing ATP inhibition. They further show that the fraction of unblocked KATP current at physiological MgATP concentrations correlates with the severity of the clinical phenotype.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum Mol GenetHome page
R. Mannikko, C. Jefferies, S. E. Flanagan, A. Hattersley, S. Ellard, and F. M. Ashcroft
Interaction between mutations in the slide helix of Kir6.2 associated with neonatal diabetes and neurological symptoms
Hum. Mol. Genet., January 29, 2010; (2010): ddp554v2 - ddp554.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. B. Pratt, F.-F. Yan, J. W. Gay, C. A. Stanley, and S.-L. Shyng
Sulfonylurea Receptor 1 Mutations That Cause Opposite Insulin Secretion Defects with Chemical Chaperone Exposure
J. Biol. Chem., March 20, 2009; 284(12): 7951 - 7959.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Winkler, R. Lutz, U. Russ, U. Quast, and J. Bryan
Analysis of Two KCNJ11 Neonatal Diabetes Mutations, V59G and V59A, and the Analogous KCNJ8 I60G Substitution: DIFFERENCES BETWEEN THE CHANNEL SUBTYPES FORMED WITH SUR1
J. Biol. Chem., March 13, 2009; 284(11): 6752 - 6762.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. I. Tarasov, T. J. Nicolson, J.-P. Riveline, T. K. Taneja, S. A. Baldwin, J. M. Baldwin, G. Charpentier, J.-F. Gautier, P. Froguel, M. Vaxillaire, et al.
A Rare Mutation in ABCC8/SUR1 Leading to Altered ATP-Sensitive K+ Channel Activity and {beta}-Cell Glucose Sensing Is Associated With Type 2 Diabetes in Adults
Diabetes, June 1, 2008; 57(6): 1595 - 1604.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
L. Aguilar-Bryan and J. Bryan
Neonatal Diabetes Mellitus
Endocr. Rev., May 1, 2008; 29(3): 265 - 291.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
F. M. Ashcroft
ATP-sensitive K+ channels and disease: from molecule to malady
Am J Physiol Endocrinol Metab, October 1, 2007; 293(4): E880 - E889.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
K. Shimomura, F. Horster, H. de Wet, S. E. Flanagan, S. Ellard, A. T. Hattersley, N. I. Wolf, F. Ashcroft, and F. Ebinger
A novel mutation causing DEND syndrome: A treatable channelopathy of pancreas and brain
Neurology, September 25, 2007; 69(13): 1342 - 1349.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
P. Proks, K. Shimomura, T. J. Craig, C. A.J. Girard, and F. M. Ashcroft
Mechanism of action of a sulphonylurea receptor SUR1 mutation (F132L) that causes DEND syndrome
Hum. Mol. Genet., August 15, 2007; 16(16): 2011 - 2019.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
P. Tammaro and F. Ashcroft
The Kir6.2-F333I mutation differentially modulates KATP channels composed of SUR1 or SUR2 subunits
J. Physiol., June 15, 2007; 581(3): 1259 - 1269.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. Masia, J. C. Koster, S. Tumini, F. Chiarelli, C. Colombo, C. G. Nichols, and F. Barbetti
An ATP-Binding Mutation (G334D) in KCNJ11 Is Associated With a Sulfonylurea-Insensitive Form of Developmental Delay, Epilepsy, and Neonatal Diabetes
Diabetes, February 1, 2007; 56(2): 328 - 336.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. I. Tarasov, H. J. Welters, S. Senkel, G. U. Ryffel, A. T. Hattersley, N. G. Morgan, and F. M. Ashcroft
A Kir6.2 Mutation Causing Neonatal Diabetes Impairs Electrical Activity and Insulin Secretion From INS-1 {beta}-Cells
Diabetes, November 1, 2006; 55(11): 3075 - 3082.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. S. Slingerland and A. T. Hattersley
Activating Mutations in the Gene Encoding Kir6.2 Alter Fetal and Postnatal Growth and Also Cause Neonatal Diabetes
J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2782 - 2788.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
P. Proks, A. L. Arnold, J. Bruining, C. Girard, S. E. Flanagan, B. Larkin, K. Colclough, A. T. Hattersley, F. M. Ashcroft, and S. Ellard
A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes
Hum. Mol. Genet., June 1, 2006; 15(11): 1793 - 1800.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
K. Shimomura, C. A.J. Girard, P. Proks, J. Nazim, J. D. Lippiat, F. Cerutti, R. Lorini, S. Ellard, A. T. Hattersley, F. Barbetti, et al.
Mutations at the Same Residue (R50) of Kir6.2 (KCNJ11) That Cause Neonatal Diabetes Produce Different Functional Effects
Diabetes, June 1, 2006; 55(6): 1705 - 1712.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
P. Proks, C. Girard, H. Baevre, P. R. Njolstad, and F. M. Ashcroft
Functional Effects of Mutations at F35 in the NH2-terminus of Kir6.2 (KCNJ11), Causing Neonatal Diabetes, and Response to Sulfonylurea Therapy
Diabetes, June 1, 2006; 55(6): 1731 - 1737.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C.-W. Lin, Y.-W. Lin, F.-F. Yan, J. Casey, M. Kochhar, E. B. Pratt, and S.-L. Shyng
Kir6.2 Mutations Associated With Neonatal Diabetes Reduce Expression of ATP-Sensitive K+ channels: Implications in Disease Mechanism and Sulfonylurea Therapy
Diabetes, June 1, 2006; 55(6): 1738 - 1746.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.